Arbutus Biopharma (ABUS) financial statements
Arbutus Biopharma reported revenue of $14M in fiscal 2025, up 28.3% a year over 9 years.
Net income was -$34M and the operating margin -271.0%, against -32973.8% in 2016.
Free cash flow was -$40M.
The diluted share count rose 261% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Arbutus Biopharma's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $11M | $6M | $6M | $7M | $11M | $39M | $18M | $6M | $14M |
| Research and development | $61M | $63M | $58M | $58M | $49M | $66M | $84M | $74M | $54M | $25M |
| Selling, general and admin | $39M | $16M | $16M | $18M | $15M | $17M | $18M | $22M | $22M | $16M |
| Operating income | -$492M | -$111M | -$90M | -$144M | -$58M | -$74M | -$65M | -$78M | -$76M | -$38M |
| Interest expense | $0 | $261,000 | $226,000 | $2M | $4M | $3M | $2M | $459,000 | $137,000 | $97,000 |
| Pre-tax income | -$489M | -$109M | -$61M | -$166M | -$64M | -$8M | -$29M | -$15M | -$2M | $12M |
| Income tax | -$105M | -$24M | -$4M | -$13M | $0 | $0 | $4M | $0 | $0 | $0 |
| Net income | -$384M | -$84M | -$57M | -$154M | -$64M | -$76M | -$69M | -$73M | -$70M | -$34M |
| EPS (diluted) | -$7.24 | -$1.56 | -$1.21 | -$2.89 | -$1.00 | -$0.83 | -$0.46 | -$0.44 | -$0.38 | -$0.17 |
| Diluted shares | 53M | 55M | 55M | 57M | 76M | 106M | 151M | 166M | 186M | 192M |
| Operating margin | -32973.8% | -1036.7% | -1510.2% | -2394.0% | -836.1% | -669.1% | -167.8% | -430.5% | -1236.7% | -271.0% |
| Net margin | -25765.5% | -788.9% | -959.8% | -2557.4% | -922.0% | -693.9% | -178.0% | -401.6% | -1133.0% | -237.9% |
Balance sheet
Fiscal years, from Arbutus Biopharma's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $131M | $126M | $125M | $91M | $123M | $191M | $184M | $132M | $123M | $92M |
| Receivables | $273,000 | $402,000 | $1M | $1M | $1M | $899,000 | $1M | $2M | $2M | $1M |
| Total current assets | $133M | $129M | $129M | $94M | $128M | $161M | $151M | $132M | $127M | $94M |
| Property, plant and equipment | $7M | $12M | $10M | $9M | $7M | $6M | $5M | $5M | $3M | $32,000 |
| Goodwill | $24M | $24M | $22M | $0 | — | — | — | — | — | — |
| Total assets | $276M | $237M | $228M | $106M | $137M | $204M | $195M | $144M | $132M | $95M |
| Total current liabilities | $11M | $15M | $11M | $8M | $10M | $11M | $33M | $22M | $16M | $6M |
| Total liabilities | $73M | $55M | $28M | $33M | $35M | $35M | $59M | $38M | $34M | $18M |
| Shareholders' equity | $203M | $182M | $200M | $73M | $102M | $169M | $137M | $106M | $97M | $77M |
| Net debt | -$23M | -$54M | -$37M | -$32M | -$52M | -$109M | -$31M | -$26M | -$36M | -$18M |
Cash flow
Fiscal years, from Arbutus Biopharma's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$58M | -$49M | -$68M | -$71M | -$51M | -$68M | -$35M | -$86M | -$65M | -$40M |
| Capital spending | $4M | $7M | $1M | $589,000 | $229,000 | $809,000 | $512,000 | $1M | $182,000 | $0 |
| Free cash flow | -$62M | -$56M | -$69M | -$72M | -$52M | -$68M | -$36M | -$87M | -$65M | -$40M |
| Stock-based compensation | $39M | $15M | $6M | $7M | $6M | $6M | $7M | $9M | $9M | $7M |
| Net borrowing | $12M | $0 | — | — | — | — | — | — | — | — |
| Free cash flow margin | -4150.3% | -522.5% | -1160.7% | -1191.1% | -747.3% | -622.0% | -91.9% | -479.3% | -1053.8% | -281.5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ABUS.
Open ABUS in InvestinglyQuestions
What was Arbutus Biopharma's revenue in 2025?
$14M in fiscal 2025, from its 10-K filing.
How much free cash flow does Arbutus Biopharma generate?
-$40M in fiscal 2025 (operating cash flow minus capital spending).
From Arbutus Biopharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.